128 related articles for article (PubMed ID: 23749864)
1. Tension pneumocephalus after administration of two 0.25 mg cabergoline tablets in MEN1-related macroprolactinoma.
Nanba K; Usui T; Nakakuki T; Shimatsu A
BMJ Case Rep; 2013 Jun; 2013():. PubMed ID: 23749864
[No Abstract] [Full Text] [Related]
2. [Cabergoline-induced tension pneumocephalus in a patient with giant invasive prolactinoma. Case report].
Castro-Castro J; Torre-Eiriz JA; Pinzón-Millán A; Pastor-Zapata A
Neurocirugia (Astur); 2011 Dec; 22(6):558-61; discussion 561. PubMed ID: 22167286
[TBL] [Abstract][Full Text] [Related]
3. Cabergoline-induced pneumocephalus in a medically treated macroprolactinoma.
Machicado JD; Varghese JM; Orlander PR
J Clin Endocrinol Metab; 2012 Oct; 97(10):3412-3. PubMed ID: 22802088
[No Abstract] [Full Text] [Related]
4. Pneumocephalus during cabergoline treatment of an invasive macroprolactinoma.
Jouret F; Col V
Acta Clin Belg; 2009; 64(5):457. PubMed ID: 19999399
[No Abstract] [Full Text] [Related]
5. [Efficacy of cabergoline in the treatment of macroprolactinoma].
Dupuy O; Le Marec E; Mayaudon H; Rilminger H; Bordier L; Bauduceau B
Presse Med; 2003 Jan; 32(2):71-2. PubMed ID: 12653031
[No Abstract] [Full Text] [Related]
6. Tumour shrinkage and chiasmal herniation after successful cabergoline treatment for a macroprolactinoma.
Marcos L; De Luis DA; Botella I; Hurtado A
Clin Endocrinol (Oxf); 2001 Jan; 54(1):126-7. PubMed ID: 11167937
[No Abstract] [Full Text] [Related]
7. Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma.
Alberiche Ruano M; Boronat Cortés M; Ojeda Pino A; Rodriguez Perez C; Gracía Nuñez M; Marrero Arencibia D; Novoa Mogollón FJ
Pituitary; 2010 Dec; 13(4):380-2. PubMed ID: 20652638
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma.
Cho EH; Lee SA; Chung JY; Koh EH; Cho YH; Kim JH; Kim CJ; Kim MS
J Korean Med Sci; 2009 Oct; 24(5):874-8. PubMed ID: 19794986
[TBL] [Abstract][Full Text] [Related]
9. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.
Raverot G; Jacob M; Jouanneau E; Delemer B; Vighetto A; Pugeat M; Borson-Chazot F
Clin Endocrinol (Oxf); 2009 Apr; 70(4):588-92. PubMed ID: 18673461
[TBL] [Abstract][Full Text] [Related]
10. SUNCT syndrome in a patient with prolactinoma and cabergoline-induced attacks.
Jiménez Caballero PE
Cephalalgia; 2007 Jan; 27(1):76-8. PubMed ID: 17212687
[TBL] [Abstract][Full Text] [Related]
11. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
Delgrange E; Maiter D; Donckier J
Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
[TBL] [Abstract][Full Text] [Related]
12. Cystic degeneration of macroprolactinoma on long-term cabergoline.
Sharif DA; Nkonge FM; Chawda S; Benjamin J; Stojanović ND
J Clin Endocrinol Metab; 2010 Aug; 95(8):3593-4. PubMed ID: 20685886
[No Abstract] [Full Text] [Related]
13. [Pharmacologic cure of a pituitary macroprolactinoma].
Hurtado Amador R; Ayala AR
Ginecol Obstet Mex; 2003 Oct; 71():522-6. PubMed ID: 15002692
[TBL] [Abstract][Full Text] [Related]
14. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
15. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
[TBL] [Abstract][Full Text] [Related]
16. Cabergoline treatment in a case of macroprolactinoma after delivery.
Falsetti L
Acta Eur Fertil; 1995; 26(3):105-7. PubMed ID: 9098469
[TBL] [Abstract][Full Text] [Related]
17. A comparison between intensive and conventional cabergoline treatment of newly diagnosed patients with macroprolactinoma.
Rastogi A; Bhansali A; Dutta P; Singh P; Vijaivergiya R; Gupta V; Sachdeva N; Bhadada SK; Walia R
Clin Endocrinol (Oxf); 2013 Sep; 79(3):409-15. PubMed ID: 23347435
[TBL] [Abstract][Full Text] [Related]
18. Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas.
Pontikides N; Krassas GE; Nikopoulou E; Kaltsas T
Pituitary; 2000 May; 2(4):277-81. PubMed ID: 11081149
[TBL] [Abstract][Full Text] [Related]
19. Pathological gambling and hypersexuality in cabergoline-treated prolactinoma.
Falhammar H; Yarker JY
Med J Aust; 2009 Jan; 190(2):97. PubMed ID: 19236300
[No Abstract] [Full Text] [Related]
20. Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma.
Davie M
J Neuropsychiatry Clin Neurosci; 2007; 19(4):473-4. PubMed ID: 18070857
[No Abstract] [Full Text] [Related]
[Next] [New Search]
